Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4585613
Max Phase: Preclinical
Molecular Formula: C28H26FN5O3S
Molecular Weight: 531.61
Molecule Type: Unknown
Associated Items:
ID: ALA4585613
Max Phase: Preclinical
Molecular Formula: C28H26FN5O3S
Molecular Weight: 531.61
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5F)c4)sc3C(=O)O)cc2)CC1
Standard InChI: InChI=1S/C28H26FN5O3S/c1-33-13-15-34(16-14-33)21-11-9-19(10-12-21)30-25-24(28(36)37)38-27(32-25)18-5-4-6-20(17-18)31-26(35)22-7-2-3-8-23(22)29/h2-12,17,30H,13-16H2,1H3,(H,31,35)(H,36,37)
Standard InChI Key: HTBRVEFPCOVMEI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 531.61 | Molecular Weight (Monoisotopic): 531.1740 | AlogP: 5.40 | #Rotatable Bonds: 7 |
Polar Surface Area: 97.80 | Molecular Species: ACID | HBA: 7 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.19 | CX Basic pKa: 7.97 | CX LogP: 4.24 | CX LogD: 4.16 |
Aromatic Rings: 4 | Heavy Atoms: 38 | QED Weighted: 0.29 | Np Likeness Score: -1.92 |
1. Guo X, Yang D, Fan Z, Zhang N, Zhao B, Huang C, Wang F, Ma R, Meng M, Deng Y.. (2019) Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines., 178 [PMID:31234030] [10.1016/j.ejmech.2019.06.035] |
Source(1):